Morgan Stanley Adjusts Editas Medicine's Price Target to $7 From $8, Keeps Underweight Rating - Marketscreener.com

1 year ago 60

Real-time Estimate Cboe BZX  -  10:55:57 2023-01-24 americium EST 8.645 USD   +5.68%

01/24/2023 | 10:50am EST MT Newswires 2023 All quality about EDITAS MEDICINE, INC. 10:50a Morgan Stanley Adjusts Editas Medicine's Price Target to $7 From $8, Keeps Underweight .. MT 01/23 SVB Securities Adjusts Price Target connected Editas Medicine to $7 From $6, Maintains Market .. MT 01/20 Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline.. AQ 01/19 Editas Medicine to Sell iNK Cell Franchise, Related Technologies to Shoreline Bioscienc.. MT 01/19 Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline.. GL 01/19 Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline.. CI 01/19 Shoreline Biosciences, Inc. entered into a definitive statement to get Editas Medic.. CI 01/10 Transcript : Editas Medicine, Inc. Presents astatine 41st Annual J.P. Morgan Health.. CI 01/10 SVB Securities Trims Price Target connected Editas Medicine to $6 From $7, Maintains Market Pe.. MT 01/09 Editas Medicine to Cut Staff by 20%, Split Research Unit Into Two; Shares Fall MT Analyst Recommendations on EDITAS MEDICINE, INC. 10:50a Morgan Stanley Adjusts Editas Medicine's Price Target to $7 From $8, Keeps Underweight .. MT 01/23 SVB Securities Adjusts Price Target connected Editas Medicine to $7 From $6, Maintains Market .. MT 01/10 SVB Securities Trims Price Target connected Editas Medicine to $6 From $7, Maintains Market Pe.. MT		Financials (USD) Sales 2022 16,6 M - - Net income 2022 -215 M - - Net currency 2022 316 M - - P/E ratio 2022 -2,62x Yield 2022 - Capitalization 550 M 550 M - EV / Sales 2022 14,1x EV / Sales 2023 20,9x Nbr of Employees 264 Free-Float 99,5% Chart EDITAS MEDICINE, INC. Duration : Period : Technical investigation trends EDITAS MEDICINE, INC. Short Term Mid-Term Long Term Trends Bearish Bearish Bearish Income Statement Evolution Consensus Sell Buy Mean consensus HOLD Number of Analysts 19 Last Close Price 8,18 $ Average people price 14,13 $ Spread / Average Target 72,7% EPS Revisions Managers and Directors Gilmore ONeill President, Chief Executive Officer & Director Michelle Robertson Chief Financial Officer & Treasurer James C. Mullen Executive Chairman Mark S. Shearman Chief Scientific Officer & Executive VP Mei Baisong Chief Medical Officer & Senior Vice President Sector and Competitors 1st jan. Capi. (M$) EDITAS MEDICINE, INC. -7.78% 550 MODERNA, INC. 9.64% 75 661 IQVIA HOLDINGS INC. 11.65% 42 488 LONZA GROUP AG 9.25% 39 802 ALNYLAM PHARMACEUTICALS, INC. -3.37% 28 369 SEAGEN INC. 3.88% 24 784

1. Homepage
2. Health
3. Morgan Stanley Adjusts Editas Medicine's Price Target to $7 From $8, Keeps Underweight Rating - Marketscreener.com